• Rocket-Like Nanomedicine Restores PDAC Stromal Homeostasis

  2026-09-09

  The reference study develops an acid-responsive, multistage nanomedicine that combines stromal remodeling with gemcitabine delivery for pancreatic ductal adenocarcinoma. Its central innovation is sequential release of halofuginone and IPR-803 to reduce stromal resistance and improve intratumoral access to gemcitabine, producing marked tumor regression in a pancreatic cancer mouse model.

• Paclitaxel (Taxol) in Cancer Research Workflows

  2026-09-09

  Build reproducible cancer research assays around Paclitaxel (Taxol), from DMSO stock preparation and dose finding to cell-cycle and microtubule readouts. This workflow also uses Paclitaxel as a mechanistically distinct comparator when studying IL-6/GP130 signaling and bazedoxifene response.

• Cefoperazone Sodium Salt: Assay Workflows

  2026-09-08

  Build reproducible MIC, MBC, and β-lactamase-resistance experiments with Cefoperazone sodium salt. This guide connects practical stock preparation and microdilution design with comparative evidence and carefully bounded biliary tract infection research.

• Metabolomics of Carbapenemase-Producing Enterobacterales

  2026-09-07

  A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing from non-producing Enterobacterales in antibiotic-free cultures. Its biomarker panel links resistance phenotypes with altered metabolic pathways and suggests a route toward faster resistance detection, while still requiring external validation.

• Metformin HCl Beyond Glucose: AMPK and Fibrosis

  2026-09-07

  Metformin Hydrochloride is increasingly valuable as a mechanistic research tool beyond glucose biology. Evidence from a rabbit vocal fold injury model and fibroblast experiments connects AMPK activation with reduced fibrotic remodeling, while highlighting the controls and translational boundaries researchers should address.

• JZL184: Selective Monoacylglycerol Lipase Inhibitor

  2026-09-05

  JZL184 is a selective monoacylglycerol lipase inhibitor that increases 2-arachidonoylglycerol availability and enables controlled endocannabinoid signaling modulation. It is a research tool for CB1 receptor mediated synaptic modulation, analgesia and antinociception research, and anxiolytic effects in rodent models.

• PPM-18: Designing Causal iNOS Assays

  2026-09-04

  PPM-18 is an NF-κB-linked inhibitor of inducible nitric oxide synthase expression for dissecting inflammatory signaling. This article presents a causal, multi-readout assay strategy that connects macrophage signaling, nitric oxide biology, and carefully bounded applications in bone research.

• Triple Inhibition in BRAFV600E Melanoma

  2026-09-04

  A 2026 study shows that eIF4F inhibition can trigger adaptive ERK1/2–EZH2 and AKT1–eIF4E signaling in BRAFV600E melanoma cells. Combining eIF4F, EZH2, and AKT1 inhibitors improved apoptosis and reduced resistance to both RocA and vemurafenib in cell and animal models.

• Anagliptin Beyond Glycemic Control

  2026-09-03

  An evidence-led perspective on Anagliptin (SK-0403) as both a DPP-4 research tool and a probe of vascular smooth-muscle physiology, with practical guidance for validating Kv channel and SERCA pump involvement.

• BIRB 796: Allosteric Precision in Translational Research

  2026-09-03

  BIRB 796, or Doramapimod, illustrates how allosteric p38α MAPK inhibition can connect target selectivity, phosphatase-aware mechanism, and translational decision-making across inflammation, apoptosis, and cancer research.

• Syringin: Designing Mechanism-Ready Assays

  2026-09-02

  Syringin natural product research is strongest when chemical identity, combination pharmacology, phenotype, and pathway evidence are integrated. This guide converts RCC findings into a reproducible assay strategy while highlighting practical limitations and interpretation safeguards.

• MEHP, AhR, and Ovarian Follicle Toxicity

  2026-09-02

  Neff and colleagues show that mono(2-ethylhexyl) phthalate disrupts mouse ovarian follicle growth and estrogen-related signaling partly through aryl hydrocarbon receptor activation. Pharmacological blockade with CH 223191 reduced several MEHP-associated effects, positioning AhR signaling as a mechanistic link between phthalate exposure, altered steroidogenesis, and reproductive toxicity.

• Hexetidine (NSC-17764) in Oral Research

  2026-09-01

  Hexetidine (NSC-17764) supports reproducible planktonic, fungal, and biofilm experiments, with particular value in oral streptococcal models. Its strongest differentiation is the measurable synergy with copper ions, which enables combination screens rather than single-agent MIC testing alone.

• Biotin (Vitamin B7) for STING Assays

  2026-09-01

  Biotin (Vitamin B7) connects metabolic enzyme studies with high-sensitivity affinity workflows, but free biotin must be distinguished from activated biotinylation reagents. This guide shows how to use it in carboxylase assays, protein labeling controls, and an experimentally testable STING–DNA capture strategy inspired by shrimp antiviral research.

• L-NMMA acetate for NO Pathway Assays

  2026-08-31

  L-NMMA acetate enables controlled, pathway-level suppression of nitric oxide synthase activity in cell, biochemical, and regenerative biology workflows. Its water compatibility and broad NOS coverage make it especially useful for testing whether nitric oxide signaling drives osteogenic, inflammatory, or pharmacological phenotypes.

8419 records 1/562 page Next 12345 下5页 Last page